Tetraphase Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.32 |
Market Cap |
$27.67 M |
Shares Outstanding |
54.26 M |
Public Float |
53 M |
Address |
480 Arsenal Street Watertown Massachusetts 02472 United States |
Employees | - |
Website | http://www.tphase.com |
Updated | 07/08/2019 |
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA. |